Israel - engelska - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - engelska - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - engelska - Ministry of Health

csl behring ltd., israel - factor viii (human); von willebrand factor - powder and solvent for solution for injection/infusion - factor viii (human) 500 iu / 10 ml; von willebrand factor 1200 iu / 10 ml - coagulation factor xiii - coagulation factor xiii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrands disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

octapharma australia pty ltd - von willebrand factor, quantity: 800 iu; factor viii, quantity: 900 iu; factor viii, quantity: 15 mg - injection, powder for - excipient ingredients: calcium chloride dihydrate; glycine; sodium chloride; sucrose; octoxinol 9; tributyl phosphate; sodium citrate dihydrate - 1. von willebrand disease (vwd): treatment of bleeding episodes including surgical bleeding in patients with von willebrand's disease when desmopressin treatment is ineffective or contraindicated. 2. haemophilia a: treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia a (congenital fviii deficiency). there are insuffcient data to recommend the use of wilate in children less than 12 years of age.

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - factor viii; von willebrand factor - powder and solvent for solution for injection - 500unit ; 1000unit

Malta - engelska - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - factor viii, human - powder and solvent for solution for injection - factor viii, human 25 iu/ml - antihemorrhagics

Malta - engelska - Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 250 iu von willebrand factor, human 190 iu - antihemorrhagics

Malta - engelska - Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 500 iu von willebrand factor, human 375 iu - antihemorrhagics

Malta - engelska - Medicines Authority

takeda manufacturing austria ag industriestrasse 67, a-1221, vienna, austria - factor viii, human, von willebrand - powder and solvent for solution for injection - factor viii, human 1000 iu von willebrand factor, human 750 iu - antihemorrhagics

USA - engelska - NLM (National Library of Medicine)

biogen inc. - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) (unii: 7pcm518ylr) ((1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) - unii:7pcm51 - (1-743)-(1638-2332)-blood-coagulation factor viii (synthetic human) fusion protein with immunoglobulin g1 (synthetic human fc domain fragment), (1444-6'),(1447-9')-bis(disulfide) with immunoglobulin g1 (synthetic human fc domain fragment) 250 [iu] in 3 ml - eloctate, antihemophilic factor (recombinant), fc fusion protein, is a recombinant dna derived, antihemophilic factor indicated in adults and children with hemophilia a (congenital factor viii deficiency) for: - on-demand treatment and control of bleeding episodes, - perioperative management of bleeding, - routine prophylaxis to reduce the frequency of bleeding episodes. limitation of use eloctate is not indicated for the treatment of von willebrand disease. eloctate is contraindicated in patients who have had life-threatening hypersensitivity reactions to eloctate or other constituents of the product. [see description (11 )] risk summary there are no studies of eloctate use in pregnant women to inform a drug-associated risk. the background risk of major birth defects and miscarriage in the indicated population is unknown; however, the background risk of major birth defects in the u.s. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. animal reproductive and devel